nodes	percent_of_prediction	percent_of_DWPC	metapath
Bimatoprost—AKR1C3—Doxorubicin—muscle cancer	0.866	1	CbGbCtD
Bimatoprost—PTGER1—renal system—muscle cancer	0.00768	0.105	CbGeAlD
Bimatoprost—AKR1C3—Podofilox—Etoposide—muscle cancer	0.00761	0.592	CbGdCrCtD
Bimatoprost—PTGER3—smooth muscle tissue—muscle cancer	0.007	0.0952	CbGeAlD
Bimatoprost—PTGER3—renal system—muscle cancer	0.00674	0.0917	CbGeAlD
Bimatoprost—PTGFR—smooth muscle tissue—muscle cancer	0.00559	0.0761	CbGeAlD
Bimatoprost—AKR1C3—Vinblastine—Vincristine—muscle cancer	0.00524	0.408	CbGdCrCtD
Bimatoprost—PTGER1—head—muscle cancer	0.00514	0.07	CbGeAlD
Bimatoprost—AKR1C3—smooth muscle tissue—muscle cancer	0.00455	0.0619	CbGeAlD
Bimatoprost—PTGER3—head—muscle cancer	0.00451	0.0613	CbGeAlD
Bimatoprost—PTGER3—testis—muscle cancer	0.00435	0.0593	CbGeAlD
Bimatoprost—PTGFR—tendon—muscle cancer	0.0042	0.0572	CbGeAlD
Bimatoprost—AKR1C3—cardiac atrium—muscle cancer	0.00392	0.0533	CbGeAlD
Bimatoprost—PTGFR—head—muscle cancer	0.0036	0.049	CbGeAlD
Bimatoprost—PTGER3—Small Ligand GPCRs—CNR1—muscle cancer	0.00355	0.153	CbGpPWpGaD
Bimatoprost—PTGFR—testis—muscle cancer	0.00348	0.0474	CbGeAlD
Bimatoprost—AKR1C3—tendon—muscle cancer	0.00342	0.0465	CbGeAlD
Bimatoprost—AKR1C3—bone marrow—muscle cancer	0.00331	0.045	CbGeAlD
Bimatoprost—AKR1C3—vagina—muscle cancer	0.00317	0.0431	CbGeAlD
Bimatoprost—Tafluprost—PTGS2—muscle cancer	0.00293	1	CrCbGaD
Bimatoprost—AKR1C3—testis—muscle cancer	0.00283	0.0385	CbGeAlD
Bimatoprost—PTGFR—Small Ligand GPCRs—CNR1—muscle cancer	0.00265	0.114	CbGpPWpGaD
Bimatoprost—PTGER1—Small Ligand GPCRs—CNR1—muscle cancer	0.0026	0.112	CbGpPWpGaD
Bimatoprost—AKR1C3—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—muscle cancer	0.00139	0.0601	CbGpPWpGaD
Bimatoprost—PTGER3—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.00107	0.0462	CbGpPWpGaD
Bimatoprost—Chronic obstructive pulmonary disease—Methotrexate—muscle cancer	0.000832	0.038	CcSEcCtD
Bimatoprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.000802	0.0346	CbGpPWpGaD
Bimatoprost—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.000785	0.0338	CbGpPWpGaD
Bimatoprost—PTGFR—GPCRs, Other—CNR1—muscle cancer	0.000758	0.0327	CbGpPWpGaD
Bimatoprost—AKR1C3—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000503	0.0217	CbGpPWpGaD
Bimatoprost—PTGER3—G alpha (i) signalling events—CNR1—muscle cancer	0.000475	0.0205	CbGpPWpGaD
Bimatoprost—PTGER3—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.00044	0.019	CbGpPWpGaD
Bimatoprost—Skin discolouration—Etoposide—muscle cancer	0.00044	0.0201	CcSEcCtD
Bimatoprost—Inflammation—Etoposide—muscle cancer	0.000409	0.0187	CcSEcCtD
Bimatoprost—Skin hyperpigmentation—Methotrexate—muscle cancer	0.0004	0.0183	CcSEcCtD
Bimatoprost—PTGER3—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000377	0.0163	CbGpPWpGaD
Bimatoprost—Urine abnormality—Doxorubicin—muscle cancer	0.000372	0.017	CcSEcCtD
Bimatoprost—Liver function test abnormal—Dactinomycin—muscle cancer	0.000368	0.0168	CcSEcCtD
Bimatoprost—Lacrimation—Doxorubicin—muscle cancer	0.00035	0.016	CcSEcCtD
Bimatoprost—Urine analysis abnormal—Doxorubicin—muscle cancer	0.00035	0.016	CcSEcCtD
Bimatoprost—Skin hyperpigmentation—Doxorubicin—muscle cancer	0.000346	0.0158	CcSEcCtD
Bimatoprost—Burning sensation—Methotrexate—muscle cancer	0.000342	0.0157	CcSEcCtD
Bimatoprost—PTGER3—GPCR ligand binding—PTCH1—muscle cancer	0.00034	0.0147	CbGpPWpGaD
Bimatoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000329	0.0142	CbGpPWpGaD
Bimatoprost—PTGER1—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000322	0.0139	CbGpPWpGaD
Bimatoprost—Keratitis—Doxorubicin—muscle cancer	0.000318	0.0145	CcSEcCtD
Bimatoprost—Burning sensation—Doxorubicin—muscle cancer	0.000296	0.0136	CcSEcCtD
Bimatoprost—PTGER3—GPCR ligand binding—CNR1—muscle cancer	0.000287	0.0124	CbGpPWpGaD
Bimatoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000282	0.0122	CbGpPWpGaD
Bimatoprost—PTGER1—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000276	0.0119	CbGpPWpGaD
Bimatoprost—Pharyngitis—Dactinomycin—muscle cancer	0.000273	0.0125	CcSEcCtD
Bimatoprost—Depression—Vincristine—muscle cancer	0.000273	0.0125	CcSEcCtD
Bimatoprost—Scotoma—Doxorubicin—muscle cancer	0.000271	0.0124	CcSEcCtD
Bimatoprost—Skin discolouration—Methotrexate—muscle cancer	0.000263	0.012	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—KIDINS220—muscle cancer	0.000262	0.0113	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR ligand binding—PTCH1—muscle cancer	0.000255	0.011	CbGpPWpGaD
Bimatoprost—Stinging—Doxorubicin—muscle cancer	0.000254	0.0116	CcSEcCtD
Bimatoprost—PTGER1—GPCR ligand binding—PTCH1—muscle cancer	0.000249	0.0107	CbGpPWpGaD
Bimatoprost—Inflammation—Methotrexate—muscle cancer	0.000245	0.0112	CcSEcCtD
Bimatoprost—Connective tissue disorder—Vincristine—muscle cancer	0.000242	0.0111	CcSEcCtD
Bimatoprost—Erythema—Dactinomycin—muscle cancer	0.00024	0.011	CcSEcCtD
Bimatoprost—Cystitis noninfective—Methotrexate—muscle cancer	0.000232	0.0106	CcSEcCtD
Bimatoprost—Cystitis—Methotrexate—muscle cancer	0.00023	0.0105	CcSEcCtD
Bimatoprost—Skin discolouration—Doxorubicin—muscle cancer	0.000228	0.0104	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000226	0.00977	CbGpPWpGaD
Bimatoprost—Cough increased—Doxorubicin—muscle cancer	0.000225	0.0103	CcSEcCtD
Bimatoprost—Lacrimation increased—Doxorubicin—muscle cancer	0.000223	0.0102	CcSEcCtD
Bimatoprost—Angiopathy—Vincristine—muscle cancer	0.000223	0.0102	CcSEcCtD
Bimatoprost—Mediastinal disorder—Vincristine—muscle cancer	0.000222	0.0101	CcSEcCtD
Bimatoprost—Bladder pain—Methotrexate—muscle cancer	0.000215	0.00983	CcSEcCtD
Bimatoprost—PTGFR—GPCR ligand binding—CNR1—muscle cancer	0.000215	0.00927	CbGpPWpGaD
Bimatoprost—Inflammation—Doxorubicin—muscle cancer	0.000212	0.00971	CcSEcCtD
Bimatoprost—PTGER1—GPCR ligand binding—CNR1—muscle cancer	0.00021	0.00907	CbGpPWpGaD
Bimatoprost—Cystitis noninfective—Doxorubicin—muscle cancer	0.000201	0.0092	CcSEcCtD
Bimatoprost—Cystitis—Doxorubicin—muscle cancer	0.000199	0.00909	CcSEcCtD
Bimatoprost—PTGFR—Signaling Pathways—KIDINS220—muscle cancer	0.000196	0.00846	CbGpPWpGaD
Bimatoprost—Infection—Dactinomycin—muscle cancer	0.000194	0.00889	CcSEcCtD
Bimatoprost—Vertigo—Vincristine—muscle cancer	0.000193	0.0088	CcSEcCtD
Bimatoprost—PTGER1—Signaling Pathways—KIDINS220—muscle cancer	0.000192	0.00828	CbGpPWpGaD
Bimatoprost—Dry eye—Doxorubicin—muscle cancer	0.00019	0.0087	CcSEcCtD
Bimatoprost—Eye disorder—Etoposide—muscle cancer	0.000186	0.00852	CcSEcCtD
Bimatoprost—Bladder pain—Doxorubicin—muscle cancer	0.000186	0.00851	CcSEcCtD
Bimatoprost—AKR1C3—Signaling Pathways—KIDINS220—muscle cancer	0.000185	0.00799	CbGpPWpGaD
Bimatoprost—Hypertension—Vincristine—muscle cancer	0.000185	0.00846	CcSEcCtD
Bimatoprost—Visual disturbance—Methotrexate—muscle cancer	0.000182	0.00833	CcSEcCtD
Bimatoprost—Angiopathy—Etoposide—muscle cancer	0.000181	0.00827	CcSEcCtD
Bimatoprost—Mediastinal disorder—Etoposide—muscle cancer	0.00018	0.00822	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism—FH—muscle cancer	0.000178	0.0077	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—PTCH1—muscle cancer	0.000175	0.00754	CbGpPWpGaD
Bimatoprost—Infection—Vincristine—muscle cancer	0.000174	0.00794	CcSEcCtD
Bimatoprost—Nervous system disorder—Vincristine—muscle cancer	0.000172	0.00784	CcSEcCtD
Bimatoprost—Pain—Dactinomycin—muscle cancer	0.000167	0.00765	CcSEcCtD
Bimatoprost—Eye pain—Doxorubicin—muscle cancer	0.000166	0.00757	CcSEcCtD
Bimatoprost—PTGER3—GPCR downstream signaling—CNR1—muscle cancer	0.000162	0.007	CbGpPWpGaD
Bimatoprost—Liver function test abnormal—Methotrexate—muscle cancer	0.000159	0.00729	CcSEcCtD
Bimatoprost—Insomnia—Vincristine—muscle cancer	0.000158	0.00723	CcSEcCtD
Bimatoprost—Vertigo—Etoposide—muscle cancer	0.000156	0.00713	CcSEcCtD
Bimatoprost—Cough—Etoposide—muscle cancer	0.000151	0.00692	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Vincristine—muscle cancer	0.000151	0.0069	CcSEcCtD
Bimatoprost—Hypertension—Etoposide—muscle cancer	0.00015	0.00685	CcSEcCtD
Bimatoprost—Pain—Vincristine—muscle cancer	0.00015	0.00684	CcSEcCtD
Bimatoprost—Diplopia—Doxorubicin—muscle cancer	0.00015	0.00683	CcSEcCtD
Bimatoprost—Asthma—Methotrexate—muscle cancer	0.000149	0.00682	CcSEcCtD
Bimatoprost—Chest pain—Etoposide—muscle cancer	0.000148	0.00676	CcSEcCtD
Bimatoprost—PTGER3—Signaling by GPCR—CNR1—muscle cancer	0.000147	0.00636	CbGpPWpGaD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000147	0.00671	CcSEcCtD
Bimatoprost—Infection—Etoposide—muscle cancer	0.000141	0.00643	CcSEcCtD
Bimatoprost—Asthenia—Dactinomycin—muscle cancer	0.00014	0.00642	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000139	0.00634	CcSEcCtD
Bimatoprost—Liver function test abnormal—Doxorubicin—muscle cancer	0.000138	0.00631	CcSEcCtD
Bimatoprost—Skin disorder—Etoposide—muscle cancer	0.000138	0.00629	CcSEcCtD
Bimatoprost—Dry skin—Doxorubicin—muscle cancer	0.000137	0.00626	CcSEcCtD
Bimatoprost—Nasopharyngitis—Doxorubicin—muscle cancer	0.000134	0.00611	CcSEcCtD
Bimatoprost—Depression—Methotrexate—muscle cancer	0.000133	0.00606	CcSEcCtD
Bimatoprost—PTGFR—Signaling by GPCR—PTCH1—muscle cancer	0.000131	0.00563	CbGpPWpGaD
Bimatoprost—Asthma—Doxorubicin—muscle cancer	0.000129	0.00591	CcSEcCtD
Bimatoprost—PTGER1—Signaling by GPCR—PTCH1—muscle cancer	0.000128	0.00552	CbGpPWpGaD
Bimatoprost—Dyspnoea—Etoposide—muscle cancer	0.000126	0.00577	CcSEcCtD
Bimatoprost—Somnolence—Etoposide—muscle cancer	0.000126	0.00576	CcSEcCtD
Bimatoprost—Asthenia—Vincristine—muscle cancer	0.000125	0.00574	CcSEcCtD
Bimatoprost—Bronchitis—Doxorubicin—muscle cancer	0.000124	0.00568	CcSEcCtD
Bimatoprost—Rash—Dactinomycin—muscle cancer	0.000123	0.00564	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Etoposide—muscle cancer	0.000122	0.00559	CcSEcCtD
Bimatoprost—PTGFR—GPCR downstream signaling—CNR1—muscle cancer	0.000121	0.00524	CbGpPWpGaD
Bimatoprost—Pain—Etoposide—muscle cancer	0.000121	0.00554	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.00012	0.00549	CcSEcCtD
Bimatoprost—PTGER1—GPCR downstream signaling—CNR1—muscle cancer	0.000119	0.00513	CbGpPWpGaD
Bimatoprost—Pharyngitis—Methotrexate—muscle cancer	0.000119	0.00542	CcSEcCtD
Bimatoprost—Nausea—Dactinomycin—muscle cancer	0.000116	0.00532	CcSEcCtD
Bimatoprost—Dizziness—Vincristine—muscle cancer	0.000116	0.00529	CcSEcCtD
Bimatoprost—Visual impairment—Methotrexate—muscle cancer	0.000115	0.00526	CcSEcCtD
Bimatoprost—Eye disorder—Methotrexate—muscle cancer	0.000112	0.0051	CcSEcCtD
Bimatoprost—Rash—Vincristine—muscle cancer	0.00011	0.00504	CcSEcCtD
Bimatoprost—PTGFR—Signaling by GPCR—CNR1—muscle cancer	0.00011	0.00476	CbGpPWpGaD
Bimatoprost—Dermatitis—Vincristine—muscle cancer	0.00011	0.00504	CcSEcCtD
Bimatoprost—AKR1C3—Disease—ENO2—muscle cancer	0.00011	0.00474	CbGpPWpGaD
Bimatoprost—Headache—Vincristine—muscle cancer	0.00011	0.00501	CcSEcCtD
Bimatoprost—Angiopathy—Methotrexate—muscle cancer	0.000108	0.00495	CcSEcCtD
Bimatoprost—Sinusitis—Doxorubicin—muscle cancer	0.000108	0.00494	CcSEcCtD
Bimatoprost—PTGER1—Signaling by GPCR—CNR1—muscle cancer	0.000108	0.00466	CbGpPWpGaD
Bimatoprost—Mediastinal disorder—Methotrexate—muscle cancer	0.000108	0.00492	CcSEcCtD
Bimatoprost—Erythema—Methotrexate—muscle cancer	0.000104	0.00475	CcSEcCtD
Bimatoprost—Nausea—Vincristine—muscle cancer	0.000104	0.00475	CcSEcCtD
Bimatoprost—Rhinitis—Doxorubicin—muscle cancer	0.000104	0.00474	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—PTCH1—muscle cancer	0.000103	0.00445	CbGpPWpGaD
Bimatoprost—Pharyngitis—Doxorubicin—muscle cancer	0.000103	0.00469	CcSEcCtD
Bimatoprost—Oedema peripheral—Doxorubicin—muscle cancer	0.000102	0.00466	CcSEcCtD
Bimatoprost—Asthenia—Etoposide—muscle cancer	0.000102	0.00465	CcSEcCtD
Bimatoprost—Connective tissue disorder—Doxorubicin—muscle cancer	0.000102	0.00465	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism—MED12—muscle cancer	0.000101	0.00435	CbGpPWpGaD
Bimatoprost—Pruritus—Etoposide—muscle cancer	0.0001	0.00458	CcSEcCtD
Bimatoprost—AKR1C3—Disease—HMGA1—muscle cancer	9.98e-05	0.0043	CbGpPWpGaD
Bimatoprost—Visual impairment—Doxorubicin—muscle cancer	9.97e-05	0.00456	CcSEcCtD
Bimatoprost—Vision blurred—Methotrexate—muscle cancer	9.8e-05	0.00448	CcSEcCtD
Bimatoprost—Eye disorder—Doxorubicin—muscle cancer	9.67e-05	0.00442	CcSEcCtD
Bimatoprost—Angiopathy—Doxorubicin—muscle cancer	9.38e-05	0.00429	CcSEcCtD
Bimatoprost—Dizziness—Etoposide—muscle cancer	9.37e-05	0.00428	CcSEcCtD
Bimatoprost—Vertigo—Methotrexate—muscle cancer	9.34e-05	0.00427	CcSEcCtD
Bimatoprost—Mediastinal disorder—Doxorubicin—muscle cancer	9.32e-05	0.00426	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism—ENO2—muscle cancer	9.19e-05	0.00397	CbGpPWpGaD
Bimatoprost—Cough—Methotrexate—muscle cancer	9.07e-05	0.00415	CcSEcCtD
Bimatoprost—Erythema—Doxorubicin—muscle cancer	9e-05	0.00412	CcSEcCtD
Bimatoprost—AKR1C3—Disease—FOXO4—muscle cancer	8.95e-05	0.00386	CbGpPWpGaD
Bimatoprost—Rash—Etoposide—muscle cancer	8.93e-05	0.00408	CcSEcCtD
Bimatoprost—Dermatitis—Etoposide—muscle cancer	8.92e-05	0.00408	CcSEcCtD
Bimatoprost—Headache—Etoposide—muscle cancer	8.88e-05	0.00406	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—FOXO4—muscle cancer	8.88e-05	0.00383	CbGpPWpGaD
Bimatoprost—Chest pain—Methotrexate—muscle cancer	8.85e-05	0.00405	CcSEcCtD
Bimatoprost—Tension—Doxorubicin—muscle cancer	8.84e-05	0.00404	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	8.79e-05	0.00402	CcSEcCtD
Bimatoprost—Nervousness—Doxorubicin—muscle cancer	8.75e-05	0.004	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—CNR1—muscle cancer	8.71e-05	0.00376	CbGpPWpGaD
Bimatoprost—Vision blurred—Doxorubicin—muscle cancer	8.49e-05	0.00388	CcSEcCtD
Bimatoprost—Infection—Methotrexate—muscle cancer	8.43e-05	0.00385	CcSEcCtD
Bimatoprost—Nausea—Etoposide—muscle cancer	8.42e-05	0.00385	CcSEcCtD
Bimatoprost—Nervous system disorder—Methotrexate—muscle cancer	8.32e-05	0.0038	CcSEcCtD
Bimatoprost—Skin disorder—Methotrexate—muscle cancer	8.24e-05	0.00377	CcSEcCtD
Bimatoprost—Vertigo—Doxorubicin—muscle cancer	8.09e-05	0.0037	CcSEcCtD
Bimatoprost—Palpitations—Doxorubicin—muscle cancer	7.96e-05	0.00364	CcSEcCtD
Bimatoprost—Cough—Doxorubicin—muscle cancer	7.86e-05	0.00359	CcSEcCtD
Bimatoprost—Hypertension—Doxorubicin—muscle cancer	7.77e-05	0.00355	CcSEcCtD
Bimatoprost—PTGFR—Signaling Pathways—PTCH1—muscle cancer	7.72e-05	0.00333	CbGpPWpGaD
Bimatoprost—Insomnia—Methotrexate—muscle cancer	7.68e-05	0.00351	CcSEcCtD
Bimatoprost—Chest pain—Doxorubicin—muscle cancer	7.67e-05	0.0035	CcSEcCtD
Bimatoprost—Anxiety—Doxorubicin—muscle cancer	7.64e-05	0.00349	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	7.61e-05	0.00348	CcSEcCtD
Bimatoprost—Dyspnoea—Methotrexate—muscle cancer	7.57e-05	0.00346	CcSEcCtD
Bimatoprost—PTGER1—Signaling Pathways—PTCH1—muscle cancer	7.55e-05	0.00326	CbGpPWpGaD
Bimatoprost—Somnolence—Methotrexate—muscle cancer	7.54e-05	0.00345	CcSEcCtD
Bimatoprost—Dry mouth—Doxorubicin—muscle cancer	7.5e-05	0.00343	CcSEcCtD
Bimatoprost—Dyspepsia—Methotrexate—muscle cancer	7.47e-05	0.00341	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Methotrexate—muscle cancer	7.33e-05	0.00335	CcSEcCtD
Bimatoprost—Infection—Doxorubicin—muscle cancer	7.3e-05	0.00334	CcSEcCtD
Bimatoprost—AKR1C3—Signaling Pathways—PTCH1—muscle cancer	7.29e-05	0.00314	CbGpPWpGaD
Bimatoprost—Pain—Methotrexate—muscle cancer	7.26e-05	0.00332	CcSEcCtD
Bimatoprost—Nervous system disorder—Doxorubicin—muscle cancer	7.21e-05	0.00329	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	7.19e-05	0.0031	CbGpPWpGaD
Bimatoprost—Skin disorder—Doxorubicin—muscle cancer	7.14e-05	0.00326	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—IGF2—muscle cancer	7.12e-05	0.00307	CbGpPWpGaD
Bimatoprost—Insomnia—Doxorubicin—muscle cancer	6.65e-05	0.00304	CcSEcCtD
Bimatoprost—PTGFR—Signaling Pathways—FOXO4—muscle cancer	6.64e-05	0.00286	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—FOXO1—muscle cancer	6.61e-05	0.00285	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—FOXO1—muscle cancer	6.55e-05	0.00283	CbGpPWpGaD
Bimatoprost—Dyspnoea—Doxorubicin—muscle cancer	6.55e-05	0.00299	CcSEcCtD
Bimatoprost—Somnolence—Doxorubicin—muscle cancer	6.53e-05	0.00299	CcSEcCtD
Bimatoprost—PTGFR—Signaling Pathways—CNR1—muscle cancer	6.51e-05	0.00281	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—FOXO4—muscle cancer	6.5e-05	0.0028	CbGpPWpGaD
Bimatoprost—Dyspepsia—Doxorubicin—muscle cancer	6.47e-05	0.00296	CcSEcCtD
Bimatoprost—PTGER1—Signaling Pathways—CNR1—muscle cancer	6.38e-05	0.00275	CbGpPWpGaD
Bimatoprost—Gastrointestinal disorder—Doxorubicin—muscle cancer	6.34e-05	0.0029	CcSEcCtD
Bimatoprost—Pain—Doxorubicin—muscle cancer	6.28e-05	0.00287	CcSEcCtD
Bimatoprost—AKR1C3—Signaling Pathways—FOXO4—muscle cancer	6.27e-05	0.0027	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—CNR1—muscle cancer	6.15e-05	0.00265	CbGpPWpGaD
Bimatoprost—Asthenia—Methotrexate—muscle cancer	6.09e-05	0.00278	CcSEcCtD
Bimatoprost—Pruritus—Methotrexate—muscle cancer	6e-05	0.00274	CcSEcCtD
Bimatoprost—Dizziness—Methotrexate—muscle cancer	5.61e-05	0.00257	CcSEcCtD
Bimatoprost—Rash—Methotrexate—muscle cancer	5.35e-05	0.00245	CcSEcCtD
Bimatoprost—Dermatitis—Methotrexate—muscle cancer	5.35e-05	0.00244	CcSEcCtD
Bimatoprost—PTGFR—Signaling Pathways—IGF2—muscle cancer	5.33e-05	0.0023	CbGpPWpGaD
Bimatoprost—Headache—Methotrexate—muscle cancer	5.32e-05	0.00243	CcSEcCtD
Bimatoprost—Asthenia—Doxorubicin—muscle cancer	5.27e-05	0.00241	CcSEcCtD
Bimatoprost—PTGER1—Signaling Pathways—IGF2—muscle cancer	5.21e-05	0.00225	CbGpPWpGaD
Bimatoprost—Pruritus—Doxorubicin—muscle cancer	5.2e-05	0.00238	CcSEcCtD
Bimatoprost—Nausea—Methotrexate—muscle cancer	5.04e-05	0.0023	CcSEcCtD
Bimatoprost—AKR1C3—Disease—KIT—muscle cancer	5.04e-05	0.00217	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—IGF2—muscle cancer	5.03e-05	0.00217	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—KIT—muscle cancer	4.99e-05	0.00215	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—FOXO1—muscle cancer	4.9e-05	0.00211	CbGpPWpGaD
Bimatoprost—Dizziness—Doxorubicin—muscle cancer	4.86e-05	0.00222	CcSEcCtD
Bimatoprost—PTGER1—Signaling Pathways—FOXO1—muscle cancer	4.8e-05	0.00207	CbGpPWpGaD
Bimatoprost—Rash—Doxorubicin—muscle cancer	4.63e-05	0.00212	CcSEcCtD
Bimatoprost—Dermatitis—Doxorubicin—muscle cancer	4.63e-05	0.00212	CcSEcCtD
Bimatoprost—AKR1C3—Signaling Pathways—FOXO1—muscle cancer	4.63e-05	0.002	CbGpPWpGaD
Bimatoprost—Headache—Doxorubicin—muscle cancer	4.6e-05	0.0021	CcSEcCtD
Bimatoprost—Nausea—Doxorubicin—muscle cancer	4.36e-05	0.002	CcSEcCtD
Bimatoprost—AKR1C3—Disease—MDM2—muscle cancer	3.97e-05	0.00171	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—MDM2—muscle cancer	3.93e-05	0.0017	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—PTGS2—muscle cancer	3.82e-05	0.00165	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—KIT—muscle cancer	3.73e-05	0.00161	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—KIT—muscle cancer	3.66e-05	0.00158	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—KIT—muscle cancer	3.53e-05	0.00152	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—PTGS2—muscle cancer	3.2e-05	0.00138	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—VEGFA—muscle cancer	2.99e-05	0.00129	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—MDM2—muscle cancer	2.94e-05	0.00127	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—MDM2—muscle cancer	2.88e-05	0.00124	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—MDM2—muscle cancer	2.78e-05	0.0012	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—TP53—muscle cancer	2.26e-05	0.000973	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—VEGFA—muscle cancer	2.23e-05	0.000963	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—VEGFA—muscle cancer	2.19e-05	0.000943	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—VEGFA—muscle cancer	2.11e-05	0.00091	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—TP53—muscle cancer	1.69e-05	0.000728	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—TP53—muscle cancer	1.65e-05	0.000712	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—TP53—muscle cancer	1.59e-05	0.000687	CbGpPWpGaD
